Incannex Healthcare Inc. (IXHL) News
Follow Incannex Healthcare Inc. (IXHL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Incannex Healthcare Inc reports results for the quarter ended June 30 - Earnings Summary
FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data September 28 at 12:37 p.m. UTC. All figures in Australian dollars unless otherwise stated. (For questions concerning the data in this repo
EARNINGS | Sep 28, 2026, 12:37 PM UTC
L
Weekly Recap: Fiscal 2026 net loss and Phase 2 IHL-42X trial progress
Incannex Healthcare Inc. (NASDAQ:IXHL) reported fiscal 2026 revenue of $0 and a $19.3M net loss (diluted loss $1.66), while advancing its IHL-42X program—completing Phase 2 RePOSA with AHI reductions and launching the Ph
EARNINGS | Sep 28, 2026, 11:04 AM UTC
L
Incannex Healthcare Inc. FY 2026: Revenue $0 Net income ($19.3M), EPS ($1.66) — 10-K Summary
Incannex Healthcare Inc. reported fiscal 2026 results with revenue of $0 and a net loss of ($19.3M), narrowing from a ($46.89M) loss in the prior year; diluted loss per share was ($1.66) versus ($40.82) in fiscal 2025.Fi
EARNINGS | Sep 25, 2026, 12:57 PM UTC
H
Incannex Healthcare Inc expected to post a loss of 75 cents a share - Earnings Preview
Incannex Healthcare Inc expected to post a loss of 75 cents a share - Earnings Preview
EARNINGS | Sep 25, 2026, 11:02 AM UTC
L
Incannex Healthcare issues corporate update on clinical, IP and capital
Incannex Healthcare Inc. (IXHL) provided a corporate update covering clinical progress, intellectual property and its capital position, per the company’s release.
EQUITY | Sep 09, 2026, 12:03 PM UTC
L
IXHL - Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
IXHL - Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
EQUITY | Sep 09, 2026, 12:02 PM UTC
M
Incannex reports first patient dosed in Phase 2 IHL-42X study
Incannex Healthcare said its DReAMzz Phase 2 IHL-42X study has dosed the first patient and that a U.S. patent was granted. The company also said it holds about $70 million in cash.
REGULATION | Sep 09, 2026, 11:33 AM UTC
L
IXHL Q4'26 results preview: EPS expected at $(0.14)
IXHL (Incannex Healthcare Inc.) is set to announce Q4'26 results on September 02, with results expected at 8:00 AM ET. Q4'26 revenue is estimated at 0 USD and EPS is expected at $(0.14).
EARNINGS | Sep 01, 2026, 11:00 AM UTC
L
Incannex (IXHL) reports first patient dosed in DReAMzz Phase 2 study
Incannex announces the first patient is dosed in its DReAMzz Phase 2 study of IHL-42X; the source provides no additional dosing schedule, results, or catalyst details.
EQUITY | Aug 25, 2026, 12:46 PM UTC
M
IXHL Secures US Patent
Incannex secures US patent grant for IHL-42X in obstructive sleep apnea
EQUITY | Jun 25, 2026, 12:00 PM UTC